Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 44 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; poloxamer; benzyl alcohol; methionine; acetic acid; water for injections; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 44 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; poloxamer; benzyl alcohol; methionine; acetic acid; water for injections; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - recombinant omega interferon of feline origin - parenteral liquid/solution/suspension - recombinant omega interferon of feline origin vaccine active 10.0 mu/ml - immunotherapy - cat | dog - adult | cat - queen | cat - tom | kitten - canine parvovirus | feline calicivirus | calicivirus (feline) | fcv | parvovirus

Filipines - anglès - FDA (Food And Drug Administration)

zuellig pharma corp - peginterferon alfa-2a (40 kd) - solution for subcutaneous injection - 135mcg/0.5ml

Filipines - anglès - FDA (Food And Drug Administration)

zuellig pharma corp - peginterferon alfa-2a (40 kd) - solution for subcutaneous injection - 180mcg/0.5ml

Estats Units - anglès - NLM (National Library of Medicine)

aim immunotech inc - interferon alfa-n3 (unii: 47bpr3v3mp) (interferon alfa-n3 - unii:47bpr3v3mp) - interferon alfa-n3 5000000 [arb'u] in 1 ml

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - interferon alfa-2b - eye drops - 1mega unit/1ml

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - interferon beta-1a, quantity: 60 microgram/ml - injection, solution - excipient ingredients: arginine hydrochloride; polysorbate 20; sodium acetate; water for injections; glacial acetic acid - avonex is indicated for the treatment of patients with relapsing forms of multiple sclerosis (ms). avonex is indicated in patients who have experienced a single demyelinating event and are at risk of developing clinically definite ms based on the presence of brain mri abnormalities characteristic of ms. avonex 60 mcg is indicated for the treatment of secondary progressive ms in patients in whom relapse is still a feature of disease. avonex 60 mcg should not be initiated in patients with secondary progressive ms who have not experienced relapse in the previous 12 months.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - interferon beta-1b, quantity: 0.25 mg/ml - injection, powder for - excipient ingredients: albumin; mannitol - betaferon is indicated for the treatment of: - ambulatory patients with relapsing-remitting multiple sclerosis (ms) characterised by at least two attacks of neurologic dysfunction over a two year period followed by complete or incomplete recovery. - betaferon is also indicated for the reduction of frequency and severity of clinical relapses, and for the slowing of progression of disease in patients with secondary progressive multiple sclerosis. - the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (mri) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - interferon gamma-1b, quantity: 4 million iu/ml - injection, solution - excipient ingredients: succinic acid; sodium succinate hexahydrate; mannitol; water for injections; polysorbate 20 - as an adjunct for reduction of the frequency of serious infections in patients with chronic granulomatous disease (cgd). the benefits of imukin have been most marked in children with cgd although imukin may be used in adult patients.